and PLD2, require phosphatidylinositol 4,5-bisphosphate for activity. However, PLD2 is fully active in the presence of this phospholipid, whereas PLD1 activation is dependent on additional factors such as ADP-ribosylation factor-1 (ARF-1) and protein kinase C␣. We find that mastoparan, an activator of G i and mast cells, stimulates an intrinsic PLD activity, most likely PLD2, in fractions enriched in plasma membranes from rat basophilic leukemia 2H3 mast cells. Overexpression of PLD2, but not of PLD1, results in a large increase in the mastoparan-inducible PLD activity in membrane fractions, particularly those enriched in plasma membranes. As in previous studies, expressed PLD2 is localized primarily in the plasma membrane and PLD1 in granule membranes. Studies with pertussis toxin and other agents indicate that mastoparan stimulates PLD2 independently of G i , ARF-1, protein kinase C, and calcium. Kinetic studies indicate that mastoparan interacts synergistically with phosphatidylinositol 4,5-bisphosphate and that oleate, itself a weak stimulant of PLD2 at low concentrations, is a competitive inhibitor of mastoparan stimulation of PLD2. Therefore, mastoparan may be useful for investigating the regulation of PLD2, particularly in view of the well studied molecular interactions of mastoparan with certain other strategic signaling proteins.
ARF and Rho proteins (8 -12) , Rho kinase (13) , calcium/ calmodulin-dependent protein kinase II (14) , and protein kinase C (PKC) in a catalytically dependent and independent manner (8, 15, 16) .
In contrast to PLD1, PLD2 is activated by PI 4,5-bisphosphate alone, and this activation is not affected by the small GTPases or PKC␣ (4) and only weakly by ARF proteins (17, 18) . PLD2 activity could conceivably be regulated in vivo by PLD2 inhibitory proteins such as the synucleins (4, 19) or by recruitment of PI 4-phosphate 5-kinase 1␣, the enzyme responsible for the intracellular synthesis of PI 4,5-bisphosphate. It has been shown that intracellular production of PI 4,5-bisphosphate is coupled to PLD activation (20 -23) and that PI 4-phosphate 5-kinase 1␣ and PLD2 interact and co-localize when these two molecules are co-expressed in cells (24) . However, there is no unambiguous evidence that any of these mechanisms operate in physiologically stimulated cells. Oleate at sub-millimolar concentrations stimulates PLD2 activity in the absence of PI 4,5-bisphosphate and synergistically stimulates PLD2 activity in the presence of PI 4,5-bisphosphate (25, 26) . At high millimolar concentrations, oleate inhibits PLD2 as well as PLD1 activities (17, 27) . The physiological significance of the effects of oleate on PLD2 is unclear.
PLD appears to be essential for stimulated secretion of granules from mast cells. Studies with pharmacologic agents in the rat (RBL-2H3) mast cell line show that PLD activation correlates closely with secretion under a variety of circumstances (28, 29) and that primary alcohols, which divert the production of phosphatidic acid by PLD to phosphatidylalcohol (referred to as a transphosphatidylation reaction), suppress secretion as well (20, 28) . Moreover, the secretory response to antigen can be reconstituted in permeabilized RBL-2H3 cells by provision of ARF-1 or the phosphatidylinositol transfer protein, either of which increases levels of phosphatidylinositol 4,5-bisphosphate and thereby restores PLD activity (20) . Both isoforms of PLD are present in RBL-2H3 cells (30) . Expression studies with wild type and mutant forms of the PLDs suggest that both isoforms participate in the secretory process (30) and that PLD1 is expressed primarily on the granule membrane and PLD2 on the plasma membrane (30, 31) .
Mastoparan, a cationic tetradecapeptide and a mast cell stimulant, can assume an amphipathic ␣-helical conformation in a hydrophobic environment and is known to mimic the interactions of physiologic proteins with target proteins such as trimeric G proteins (32) and calmodulin (33, 34) . It has also been reported that mastoparan inhibits ARF1-stimulated PLD activity (35) , now recognized as PLD1, in cytosol-depleted cells, although more recent reports suggest that mastoparan is a stimulant of PLD in intact cells (36 -38) . While investigating the mechanisms of action of mastoparan and other compounds thought to stimulate mast cell secretion through the G protein G i (39), we found that mastoparan is a uniquely strong stimulant of PLD in the cultured RBL-2H3 mast cells. These and additional studies with membrane fractions from normal RBL-2H3 cells and cells made to overexpress PLD1 or PLD2 show that mastoparan selectively activates PLD2 in the plasma membrane independently of any action on G i .
EXPERIMENTAL PROCEDURES
Materials-The following materials were purchased from the indicated sources. Mastoparan and other secretagogues came from Bachem (Torrance, CA), L-␣-phosphatidyl-D-myo-inositol 4,5-bisphosphate (PI 4,5-bisphosphate) from Roche Molecular Biochemicals, GDP␤S, GTP␥S, L-␣-dipalmitoylphosphatidylcholine, and oleic acid from Sigma, phosphatidylethanolamine from Avanti Polar Lipids (Alabaster, Al), [choline-methyl- 3 H]dipalmitoylphosphatidylcholine (50 Ci/mmol) from PerkinElmer Life Sciences, pertussis toxin from List Biologicals (Campbell, CA), cell culture reagents and 60% Iodixanol (OptiPrep) from Invitrogen, and Tris-glycine polyacrylamide gels from Novex (San Diego, CA).
Cell Culture and Experimental Conditions-RBL-2H3 cells were grown as monolayers in minimal essential medium with Earle's salts and supplemented with glutamine, antibiotics, and 15% fetal bovine serum (40) . Where indicated, pertussis toxin (0.2 g/ml) was added 3 h before the experiment or the lysis of cells for the preparation of membrane fractions. (41) . Radiolabeled phosphatidylethanol was isolated and quantified by minor modifications of previously described procedures (42) . The reaction was terminated by the addition (0.75 ml/well) of a mixture of chloroform/ methanol/4 N HCl (100:200:2) (v/v/v) to form a single phase that was subsequently separated into two phases by the addition of 0.25 ml of chloroform, which contained 30 g each of unlabeled phosphatidic acid and phosphatidylethanol as well as 0.25 ml of 0.1 N HCl. A 0.5-ml sample of the lower chloroform phase was evaporated to dryness under nitrogen. The residue was dissolved in 100 l of a mixture of chloroform/ methanol (2:1) of which 25 l was placed on a silica gel-plated sheet for thin layer chromatography in a mixture of chloroform/methanol/glacial acetic acid (65:15:2) (v/v/v) (43) . The sheet was air-dried and then exposed to iodine vapor to visualize phospholipids. Regions containing phosphatidic acid and phosphatidylethanol were excised for an assay of tritium.
Measurement of PLD Activity in Intact Cells
Transient Transfection of Cells with HA-tagged PLDs-HA-tagged plasmids for PLD were kindly supplied by Dr. Michael A. Subcellular Fractionation-Cultured RBL-2H3 cells (10 7 cells) were detached from confluent cultures with 20 mM EDTA in ice-cold phosphate-buffered saline. Cells were pelleted (1,000 ϫ g for 10 min) and resuspended in 2 ml of homogenization buffer (10 mM HEPES, pH7.4, 1 mM EDTA, 0.25 M sucrose, supplemented with a protease inhibitor mixture). The cells were disrupted in a Dounce homogenizer (15 strokes). Nuclei and unbroken cells were removed by centrifuging the homogenate at 3,000 ϫ g for 10 min, resuspending the pellet in 2 ml of buffer, and repeating the centrifugation step. The supernatant (postnuclear) fractions from both centrifugation steps were combined and centrifuged at 80,000 ϫ g for 1 h. The postnuclear pellet was resuspended in 1.0 ml of homogenization buffer. All operations were carried out at 4°C.
A stock solution of 50% iodixanol was prepared by diluting OptiPrep with a solution of 0.25 M sucrose, 6 mM EDTA, and 60 mM HEPES (pH7.4) from which linear gradients of 1-20% iodixanol were formed using a gradient maker exactly as described (44) . The resuspended postnuclear fraction was loaded on top of the gradient and centrifuged in a Beckman SW41 rotor at 200,000 ϫ g for 3 h at 4°C. Sequential 1-ml fractions (gradient fractions) were then collected from the bottom of the gradient for an assay of subcellular markers and HA-tagged PLD as described below.
Ten microliters from each gradient fraction were mixed with Laemmli buffer, and the proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blotted for calnexin (anti-calnexin C terminus polyclonal antibody, Stress Gen, Victoria, British Columbia, Canada), rat mast cell protease II (anti-RMCP II antibody from Moredun Animal Health, Midlothian, Scotland), and Fc⑀RI␤ (antibody was a gift from Dr. Juan Rivera, NIAMS, National Institutes of Health) for the detection of endoplasmic reticulum, granule membrane, and plasma membrane, respectively. The relative amounts of protein were assessed by densitometric scanning. A procedure based on the addition of [ 3 H]galactose onto the oligosaccharide moieties of ovomucoid was used for the assay of galactosyltransferase activity in Golgi-containing fractions as described by others (45) .
Assay of PLD in Subcellular Fractions-Postnuclear and gradient fractions were assayed for HA-tagged PLDs by gel electrophoresis and immunoblotting (anti-HA antibody from Upstate Biotechnology, Lake Placid, NY) as described above and for PLD activity. PLD activity was assayed by the measurement of 
RESULTS

Mastoparan Stimulates PLD in Cell Membrane Fractions-An assay of PLD activity in intact RBL-2H3 cells by the transphosphatidylation assay (see "Experimental Procedures")
showed that mastoparan was a particularly strong stimulant of PLD when compared with its inactive analog, mastoparan 17, and other agents thought to stimulate mast cell degranulation via G i (Fig. 1A) . The assay of PLD activity in vitro by the [ 3 H]choline release assay showed that the mastoparan-stimulated PLD activity appeared to reside in the membrane pellet fraction of these cells (Fig. 1B) . Separation of the postnuclear membrane fraction into different fractions by density gradient centrifugation revealed that the mastoparan-stimulated PLD activity varied among these fractions (Fig. 2A) . The mastoparan-stimulated activity appeared to be distributed in fractions FIG. 4 . Expressed PLD2 is located predominantly in the plasma membrane. Post-nuclear cell membrane fractions from HA-PLD2 transfected cells were fractionated by density gradient centrifugation as described for Fig. 1 
and blotted for HA-PLD2 and cell markers (panel A).
Peak fractions were also assayed for PLD activity by measurement of enriched with the plasma membrane marker (Fc⑀RI␤) and, perhaps to a lesser extent, the granule marker (RMCPII) (Fig.  2B ). In the same experiments, ARF-1/GTP␥S elicited a modest stimulation of a PLD activity, presumed to be PLD1, primarily in fractions enriched in endoplasmic reticulum (calnexin; fractions 1 and 2) and granule membranes (RMCPII; fractions 9 -12). The extent of stimulation was at least ten times less than that achieved with mastoparan ( Fig. 2A) . These studies indicated that mastoparan was a remarkably strong stimulant of PLD activity in vivo and in vitro and that the stimulated PLD activity was unlikely to be PLD1.
Mastoparan Activates Expressed HA-tagged PLD2, but Not PLD1, in Post-nuclear Membrane Fractions-Transient expression studies showed that mastoparan had little or no stimulatory activity on supernatant or membrane fractions from cells containing gene vector or cells made to express HA-PLD1 when compared with cells made to express HA-PLD2 (Fig. 3A) . In the latter cells, the membrane fraction, but not the supernatant fraction, exhibited an extraordinarily high PLD activity in response to mastoparan (Fig. 3A) . This response was ϳ15-fold greater than that achieved with ARF-1/GTP␥S in the same membrane fraction. The selective activation of PLD2 was also apparent in studies with COS7 cells made to express HA-PLD1 or HA-PLD2. As in RBL-2H3 cells, mastoparan produced a robust stimulation of PLD only in the membrane fraction from COS7 cells that expressed HA-PLD2 (Fig 3B) .
Prior treatment of cells with pertussis toxin to inactivate the ␣-subunit of G i , a primary target of mastoparan in mast cells (39) , failed to diminish the PLD response to mastoparan in intact cells (data not shown) or in membrane fractions collected from cells made to express HA-PLD2 (Fig. 3C) . Mastoparan stimulation of HA-PLD2 in membrane fractions was also undiminished in the presence of the PKC inhibitor Ro 31-7549 (47, 48) , and EGTA (Fig. 3D) . Collectively, the results indicated that mastoparan stimulation of membrane PLD2 in vitro is independent of G i , PKC, and calcium. These results were consistent with previous reports that mastoparan stimulation of PLD in intact cells was unaffected by inhibitors of G-proteins (37) and PKC or by chelation of extracellular calcium (36) .
Mastoparan-sensitive PLD2 Is Located in the Plasma Membranes-In additional experiments with cells made to express HA-PLD2, separation of membrane fractions by density gradient demonstrated that the distribution of HA-PLD2 (Fig. 4A) and mastoparan-stimulated PLD2 activity (Fig. 4B) overlapped with the distribution of the endoplasmic reticulum marker (calnexin) and plasma membrane marker (Fc⑀RI). Although the fit was not perfect, the distribution of HA-PLD2 and mastoparan-stimulated activity appeared to best correlate with the distribution of Fc⑀RI␤ with maximum amounts of each in fraction 5. Consistent with previous studies (26, 30) , however, fluorescence microscopy of cells made to express PLDs tagged with green fluorescence protein showed that PLD2 was located largely in the plasma membrane, whereas PLD1 was located largely on granules (Fig. 4C) . brane protein in membrane fractions obtained from cells made to express HA-PLD1 or the HA vector (Fig. 5A ). Significant and maximal release occurred with 1 and 30 M mastoparan, respectively (Fig. 5B) . With 30 M mastoparan, release was initially rapid but continued for up to 80 min (Fig. 5C ). Approximately 30% of the substrate was consumed during the course of these experiments. On the assumption that this 30% was the maximum amount of substrate that was available for hydrolysis by PLD2, the analysis of the data in Fig. 5C indicated second order reaction kinetics with half-lives of 2 and 45 min for each rate component. Regardless of the reason for the second order component, we presume that any inactivation of PLD2 during the course of incubation must be as slow or slower than the second component.
Enzymatic Characteristics of PLD2 Activation by Mastoparan and the Interactions with PI 4,5-Bisphosphate-Additional
Additional studies with the membrane fraction from HA-PLD2-transfected cells suggested that mastoparan did not alter the affinity or availability of substrate for PLD2 but rather the rate of release of [ 3 H]choline in response to the addition of PI 4,5-bisphosphate. Measurement of the rate of release with different concentrations of substrate (Fig. 6A ) and replotting the data as a double-reciprocal plot (inset, Fig. 6A ) indicated that the maximal rate (V max ) was increased, whereas the affinity (apparent K m ) was unchanged. When the concentration of PI 4,5-bisphosphate was altered (Fig. 6B, open symbols) , near maximal rates of [ 3 H]choline release were observed with 6 M PI 4,5-bisphosphate (the concentration used in previous assays). In the presence of mastoparan, release of [ 3 H]choline was enhanced ϳ3.5-fold (Fig. 6B, solid symbols (25), we tested the effects of oleate on mastoparan stimulation of PLD2 in the membrane fraction from HA-PLD2-transfected cells. Oleate in the presence of PI 4,5-bisphosphate caused some additional stimulation of PLD2 at 0.1 mM and inhibited PLD2 activity at higher concentrations consistent with previous reports (inset, Fig. 7A ). Mastoparan was a much more robust stimulant than oleate. However, the stimulation of PLD2 by mastoparan was inhibited by oleate in a dose-dependent manner (Fig. 7) . The parallel shift in curves (as in Fig. 7 ) could be indicative of competitive inhibition by oleate.
DISCUSSION
Mastoparan activates endogenous PLD in intact RBL-2H3 cells and in isolated preparations enriched in plasma membranes where PLD2 is located. This activation was apparent when PLD activity was assessed by the transphosphatidylation assay in intact cells and by a [ 3 H]choline release assay in membrane preparations. The studies with expressed PLD isoforms confirm that mastoparan selectively activates PLD2 in membrane preparations in both RBL-2H3 and COS7 cells. The activation of PLD2 is not dependent on G␣ i , PKC, or calcium. This is in contrast to the stimulation of PLD and the secretion by compound 48/80 and other polybasic secretagogues in intact mast cells, where these responses are mediated via G␣ i , and are dependent on PKC or calcium (49, 50) . Therefore, mastoparan has additional activities distinct from its ability to activate G␣ i ; one of them apparently is the ability to activate PLD2 but not PLD1 in membrane preparations.
Mastoparan can assume an amphipathic ␣-helical conformation on passing from an aqueous to lipid environment and, by so doing, can mimic the interactions of physiologic ␣-helical proteins with key signaling molecules such as G i with receptors (32) and calmodulin with calmodulin-binding proteins. With respect to calmodulin, mastoparan binds with exceptionally high affinity in a calcium-dependent manner (33) resulting in possible displacement of calmodulin-binding proteins (34) . Mastoparan assumes a helical conformation within the globular Ca 2ϩ /calmodulin/mastoparan complex in a manner that is thought to reproduce the interaction of calmodulin with target proteins (51) . Calmodulin has been proposed as a negative regulator of basal PLD2 activity on the basis of the effects of calmodulin inhibitors (52) . Whether mastoparan unmasks latent PLD2 activity by disabling the inhibitory activity of calmodulin or that of other, better characterized inhibitors of PLD such as the synucleins (7) is unknown but worthy of further investigation. In particular, the synucleins possess conserved amphipathic ␣-helical domains (53), are potent inhibitors of PLD2 (4, 19) , and are present in abundant amounts in RBL-2H3 membranes. 2 It is possible also that mastoparan interacts directly with PLD2 because it can stimulate PLD2 in the absence of, and to the same extent as, PI 4,5-bisphosphosphate and yet act in synergy with PI 4,5-bisphosphate. Moreover, the studies with oleate and mastoparan (Fig. 7) suggest that these two agents compete for the same site and that occupation of this site by mastoparan and, to a much lesser extent, oleate, causes activation of PLD2 in the absence of PI 4,5-bisphosphate. The ability of mastoparan (this paper) and oleate (25) to act in synergy with PI 4,5-bisphosphate suggests further that the mastoparan/oleate-binding site is distinct from the PI 4,5-bisphosphate-binding site. In this context, oleate appears to act as a partial agonist or antagonist and mastoparan as a full agonist, because oleate inhibits stimulation of PLD2 by mastoparan. If this scenario is correct and the physiologic ligand for the mastoparan/oleate-binding site is a regulator of PLD2 activity, mastoparan might be a useful probe for studies of PLD2 in view of the well studied molecular interactions of mastoparan with other strategic signaling molecules.
